Welcome to BIOTZER
Innovative Biotech Solutions
Dedicated to advancing human health through innovative life sciences solutions. Our mission is to enable safer, faster, and more reliable biopharma and diagnostic development across Europe and beyond.
Headquartered in the House of BioHealth, we partner with leading research institutions, startups, and global healthcare companies to deliver high-quality, science-driven services and products. Whether supporting advanced cell and gene therapies, building robust analytical frameworks, or enabling next-generation diagnostics, our focus is always on quality, compliance, and patient safety.
Together, we turn groundbreaking science into meaningful healthcare impact.
Our Commitment to Innovation
BIOTZER is a leading biotech holding company dedicated to providing cutting-edge solutions, advancements in manufacturing, and innovative research and development in the fields of life science and microbiology. Our commitment to pushing the boundaries of innovation sets us apart in the biotech industry, driving us to create impactful solutions that shape the future of biotechnology.
Advancing Next-Generation Diagnostics Through Science & Collaboration
BIOTZER is a biotechnology company developing and commercializing advanced diagnostic solutions powered by Next Generation Sequencing (NGS), in close collaboration with leading academic and clinical institutions.
Through strategic collaborations with the Luxembourg Institute of Health (LIH) and the University of Luxembourg – Luxembourg Centre for Systems Biomedicine (LCSB), BIOTZER translates cutting-edge research into clinically actionable diagnostic tools.
Our development pipeline focuses on high-impact clinical areas where precision diagnostics can directly improve patient outcomes, treatment decisions, and disease monitoring.
Focus Areas
Next Generation Sequencing (NGS) Platforms
-
Development of NGS-based assays for high-sensitivity and high-specificity clinical applications
-
Scalable solutions designed for research, translational, and clinical settings
Minimal Residual Disease (MRD) – Hematological Cancers
-
Ultra-sensitive detection of residual disease
-
Supporting treatment monitoring, relapse prediction, and personalized therapy decisions
Transplantation & Graft Monitoring
-
NGS-driven molecular monitoring of graft status
-
Early detection of post-transplant complications and graft dynamics
Viral & Respiratory Diagnostics
-
NGS-driven approaches for pathogen detection and surveillance
-
Applications across infectious disease monitoring and outbreak preparedness
IP Commercialisation & Translational Diagnostics
BIOTZER is actively engaged in the commercialisation of diagnostic intellectual property, originating from academic and translational research.
Our portfolio includes diagnostic concepts targeting neurological, oncological, and complex disease indications, with a clear pathway toward clinical validation and market deployment.
Partnerships
Research Tools
Empowering Scientific Discovery
Our research tools are at the forefront of scientific exploration, enabling researchers to make groundbreaking discoveries and advancements in the field of life science and microbiology. We provide state-of-the-art equipment and resources to drive innovation and progress.
Manufacturing Solutions
Innovative Production Processes
Our manufacturing solutions integrate cutting-edge technologies to streamline production processes and enhance efficiency. We offer scalable and sustainable manufacturing options that uphold the highest standards of quality and compliance.
R&D Services
Driving Innovation Forward
Our research and development services focus on pioneering new solutions and technologies that address the challenges faced in the biotech industry. We are dedicated to driving innovation forward and creating impactful changes that benefit society and the environment.
